Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Callan JMB Inc. - SIC # 2642 -
Ticker
Exchange
SIC #
Website
Latest Ticker
CJMB
Nasdaq
2642
callanjmb.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Callan JMB Inc.
Callan JMB Launches The Atlas Complex in Alabama to Successfully Achieve the Capture of Significant Pharmaceutical Onshoring Demand and Expand U.S. Supply Chain Infrastructure
- Apr 20th, 2026 6:00 am
Callan JMB Issues Statement on Recently Filed Lawsuit by Eddie Patent Holdings LLC
- Apr 17th, 2026 3:00 pm
Callan JMB Successfully Deploys Rapid Redistribution of Critical Pharmaceuticals to Combat Localized Disease Outbreaks for Longstanding Customer
- Apr 7th, 2026 6:45 am
Callan JMB Reports Full Year 2025 Financial Results and Provides Business Update
- Mar 31st, 2026 2:05 pm
Callan JMB Supports U.S. Scale-Up of Multi-Indication Immune Platform with Phase 2b/3 Advancement
- Mar 27th, 2026 6:45 am
DifGen Pharmaceuticals and Aveva Drug Delivery Systems Lead U.S. Technology Transfer and Platform Development Collaboration for Multi-Indication Immune Restoration Therapy with Active IND Programs and Phase 2b/3 Authorization in PASC
- Mar 25th, 2026 6:37 am
Callan JMB Inc. to Oversee Manufacturing and Quality Control of Attune Biotech’s IND Clinical Trials for lodonal™ in the Treatment of Long COVID
- Mar 11th, 2026 6:45 am
Updated Lineup Announced for the iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10-11, 2026
- Mar 10th, 2026 7:00 am
iAccess Alpha Virtual Best Ideas Spring Investment Conference March 10–11, 2026
- Mar 4th, 2026 7:00 am
Callan JMB CEO, Wayne Williams Invited to Attend the 50th International GMP Conference on March 2-5, 2026
- Mar 2nd, 2026 6:45 am
Callan JMB Announces Participation in the iAccess Alpha Virtual Best Ideas Spring Investment Conference on March 10–11, 2026
- Feb 27th, 2026 6:45 am
DealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's Event
- Jan 23rd, 2026 12:50 pm
Callan JMB Announces Participation in the DealFlow Discovery Conference on January 28-29, 2026
- Jan 20th, 2026 7:00 am
Top Midday Gainers
- Jan 15th, 2026 12:05 pm
BC-Most Active Stocks
- Jan 15th, 2026 8:30 am
Callan JMB Signs Manufacturing Oversight, Federal Deployment, and Commercialization Agreement of Multi-Asset Therapeutic Pipeline with Attune for Approximately $50 to $75 Million in Total Revenue
- Jan 15th, 2026 6:45 am
Callan JMB Inc. (NASDAQ:CJMB) Announces Major Strategic Pivot to Cold-Chain Infrastructure for the $100 Billion GLP-1 Pharmaceutical Market; Initiates Retrofitting of Texas cGMP Facility
- Jan 12th, 2026 6:00 am
Founder of Callan JMB Picks Up 1.3% More Stock
- Dec 15th, 2025 3:02 am
Callan JMB Announces Third Quarter 2025 Financial Results and Provides Business Update
- Nov 14th, 2025 2:05 pm
Callan JMB Enters Agreement to Install Oral Drug Delivery Equipment in Texas Facility
- Nov 13th, 2025 7:00 am
Scroll